TIDMOPTI

OptiBiotix Health PLC

20 June 2022

20 June 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company")

ProBiotix Health - Appointment of Chief Executive Officer

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, notes the announcement (14 June 2022) by ProBiotix Health plc (AQSE: PBX) ("ProBiotix Health"), that Steen Andersen ("Steen") has been appointed as Chief Executive Officer ("CEO"), and that Steen will join the company after completing his notice period with his current employer. The Company has a 44 per cent. shareholding in ProBiotix Health.

This is part of a long-planned strategy by OptiBiotix and its portfolio companies (the "Group") to appoint experienced industry commercial leaders to each part of the business allowing the Group CEO to focus on identifying, developing and acquiring the new technologies or companies that will provide the Group with a pipeline of products and applications to deliver future growth and market value. This structure gives shareholders exposure to multiple opportunities within the emerging microbiome space and affords the potential to deliver additional value through separate public listing of the businesses and dividend return as achieved with the listing of ProBiotix Health earlier in the year.

Stephen O'Hara, CEO of OptiBiotix, commented: "The appointment of Steen as CEO of ProBiotix Health will help accelerate the growth and recognition of the business into its next phase of evolution. Having established international sales and brand awareness of its award winning LP(LDL) (R) probiotic as an ingredient, ProBiotix Health is now investing in building a presence in the dairy industry, extending the range of applications for LP(LDL) (R) into other areas of health, and increasing access to the USA and Asian markets."

For further information, please contact:

 
 OptiBiotix Health plc                                                       www.optibiotix.com 
 Stephen O'Hara, Chief Executive                                     Contact via Walbrook below 
 
 finnCap (Broker)                                                            Tel: 020 7220 0500 
 Adrian Hargrave / Scott Mathieson / Kate 
  Bannatyne (Corporate Finance) 
 Abigail Wayne (Corporate Broking) 
 
 Walbrook PR Ltd                                Tel: 020 7933 8780 or optibiotix@walbrookpr.com 
 Anna Dunphy                                                                 Mob: 07876 741 001 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFLFISREIDLIF

(END) Dow Jones Newswires

June 20, 2022 02:00 ET (06:00 GMT)

Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Lug 2022 a Ago 2022 Clicca qui per i Grafici di Optibiotix Health
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Ago 2021 a Ago 2022 Clicca qui per i Grafici di Optibiotix Health